Skip to main content
ENLV logo

Enlivex Ltd. (ENLV) Stock Price & Analysis

Enlivex Ltd. (ENLV) — MoonshotScore 55/100 (Fair band), calculated Nov 18, 2026. Price $1.17 (-2.50%), as of the Nov 19, 2026 trading session.

Educational signal · not a buy or sell recommendation · How to read this

$1.17 −$0.03 (-2.50%)

Enlivex Ltd. · ENLV · NASDAQ

Enlivex Therapeutics Ltd. is a clinical-stage macrophage reprogramming immunotherapy company. Their lead drug candidate, Allocetra, is being developed for the treatment of organ dysfunction and failure associated with sepsis and solid tumors.

Price as of Nov 19, 2026

Key Statistics

55 of 100

MoonshotScore v2 · Enlivex (ENLV)

Fair
Business Quality Solid (72)
Financial Safety Sound (71)
Valuation Fair (66)
Growth Durability Fading (34)
Momentum Falling (11)
Why this rating? Method, drivers & history

Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.

  • Business Quality — Is this a genuinely good business?
  • Financial Safety — Could this blow up on me?
  • Valuation — Am I paying a fair price?
  • Growth Durability — Is the growth real and likely to last?
  • Momentum — Is the market already moving on this?
The ten-second read ·

High quality and a strong balance sheet, but weak growth, and the price trend has turned against it. The score also carries a risk penalty for a bankruptcy-risk score in the grey zone. Business Quality: Solid; Financial Safety: Sound; Valuation: Fair; Growth Durability: Fading; Momentum: Falling.

  • EPS beat 5 of the last 8 reports
  • Altman Z 1.78 · Piotroski F 3
  • ROE 211.0% · ROA 83.8% · free-cash-flow yield -80.7%

Holding back: soft growth, weak price trend

Helping: business quality, balance-sheet strength

What has the MoonshotScore done over time?

MoonshotScore snapshots recorded for ENLV (52 recorded, newest six shown)
RecordedScoreBand
53Fair
53Fair
53Fair
53Fair
55Fair
55Fair

Daily score refresh is delayed. This is the last recorded calculation.

Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.

Computed · How the MoonshotScore is computed →

Price & valuation

As of
MeasureValue
Latest provided price$1.17
Change on the day-2.50%
Price / earnings (trailing)0.00
Shares traded on the day70.9K

Price & events

Other perspectives

Council score for Enlivex (ENLV): perspectives

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

5-Factor Breakdown

Business Quality Moderate
Financial Safety Moderate
Valuation Moderate
Growth Durability Weak
Momentum Negative

Legends Council

5 lenses, 0 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Dalio-style lens (simulated) Ray Dalio Favorable read
Griffin-style lens (simulated) Ken Griffin Favorable read
Englander-style lens (simulated) Izzy Englander Favorable read
Klarman-style lens (simulated) Seth Klarman Unfavorable read
Moon AI lens (model) Favorable read

Read on: Oct 8, 2026 · older than the 27 hours refresh window; not a current reading

Munger's Mindset

Balance Sheet & Valuation · historical

Financial Health Neutral
Margin of Safety Undervalued
Profit Margin Weak
Revenue Growth Weak
Debt/Equity Strong
ROE Strong
Gross Margin Negative

Read on: Sep 10, 2026 · older than the 27 hours refresh window; not a current reading

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

On Sep 10, 2026, the Munger lens read the price at that time as undervalued against its own estimate of value.

Readings on this page are from Nov 20, 2026, except a card that shows its own read date.

1 · What is it?

What is Enlivex (ENLV), and what does it report?

Short answer · as of

A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Enlivex Ltd. (ENLV) is listed on NASDAQ. It employs 34 people.

2 · Latest results

What do the latest results show for Enlivex (ENLV)?

Short answer · as of

Against analyst estimates the company has EPS beat 5 of the last 8 reports.

3 · Financial strengths and risks

What are the financial strengths and risks for Enlivex (ENLV)?

Short answer · as of

The MoonshotScore pillars rate business quality, balance-sheet strength as strengths. What is holding it back is soft growth, weak price trend. The distress and quality screens read Altman Z 1.78 · Piotroski F 3. Trailing ratios: ROE 211.0% · ROA 83.8% · free-cash-flow yield -80.7%.

Data-derived red flags

  • Financial-distress signal — its Altman Z-Score of 1.78 sits in the distress zone (elevated bankruptcy risk).
  • Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
4 · What to check next?

What should you watch next at Enlivex (ENLV)?

Short answer · as of

Analyst estimates on file carry FY2026 revenue $0.00 · EPS -18.40 · 0 analysts.

What the records here don't tell us

  • The next earnings date is not yet scheduled in the calendar we read.
  • No insider Form 4 transaction falls inside the window this page reads.
  • No quarterly income statement is held for ENLV.

Checked against the records this page reads, on the dates shown above.

5 · Peer comparison

How does Enlivex compare with its peers?

Short answer

Enlivex's score ranks 13th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.

Peer set — price, market value and MoonshotScore
CompanyPriceMarket valueScore
Exelixis, Inc. (EXEL) Same industry, near in market value$65.83 Nov 19, 2026$16.1B98 5-pillar Nov 18, 2026
United Therapeutics Corporation (UTHR) Same industry, near in market value$577.34 Nov 18, 2026$24.6B97 5-pillar Nov 18, 2026
argenx SE (ARGX) Same industry, near in market value$942.04 Nov 19, 2026$59.2B96 5-pillar Nov 18, 2026
Ascendis Pharma A/S (ASND) Same industry, near in market value$255.96 Nov 19, 2026$16.8B96 5-pillar Nov 18, 2026
Regeneron Pharmaceuticals, Inc. (REGN) Same industry, near in market value$945.53 Nov 18, 2026$97.8B95 5-pillar Nov 18, 2026
Neurocrine Biosciences, Inc. (NBIX) Same industry, near in market value$162.86 Nov 18, 2026$16.5B95 5-pillar Nov 18, 2026
Halozyme Therapeutics, Inc. (HALO) Same industry, near in market value$93.04 Nov 19, 2026$10.6B95 5-pillar Nov 18, 2026
Bio-Techne Corporation (TECH) Same industry, near in market value$72.70 Nov 19, 2026$11.4B92 5-pillar Nov 18, 2026
Incyte Corporation (INCY) Same industry, near in market value$117.80 Nov 18, 2026$24.0B91 5-pillar Nov 18, 2026
Vertex Pharmaceuticals Incorporated (VRTX) Same industry, near in market value$536.45 Nov 18, 2026$136B90 5-pillar Nov 18, 2026
TG Therapeutics, Inc. (TGTX) Same industry, near in market value$64.88 Nov 19, 2026$9.81B90 5-pillar Nov 18, 2026
Novo Nordisk A/S (NVO) Same industry, near in market value$38.87 Nov 19, 2026$171B87 5-pillar Nov 18, 2026
Enlivex (ENLV) — this page$1.17—55

Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.

The records behind this page

Analyst targets & estimates

What analysts have on file

Revenue estimate
$0.00
EPS estimate
$-18.40

Measured against a quoted price of $1.17 (as of Nov 19, 2026).

Who holds the shares?

Institutional ownership reported through 13F filings.

Tracked investors

Which of the 16 named investors we follow held ENLV in their latest 13F filing, and what they did against the filing before it.

InvestorManager13F quarterPortfolio weightValueLast quarter
ARK InvestCathie WoodQ3 20260%$0Sold out (was $1.31M)

See all tracked investor portfolios

How to read these figures

These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.

Enlivex Stock: Key Questions Answered

These answers are editorial: 1 of these 9 answers is drawn from the ENLV research dossier (written May 10, 2026 by gemini-2.0-flash); the other 8 are question templates that restate figures shown above. Figures in this section are not part of the source register.

What does the MoonshotScore mean for ENLV?

ENLV carries the MoonshotScore stated above — the Fair band. This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers. Enlivex Therapeutics Ltd. is a clinical-stage macrophage reprogramming immunotherapy company.

Is ENLV a good stock to buy?

Stock Expert AI does not rate ENLV buy, sell or hold. Enlivex Ltd. carries a MoonshotScore, in the Fair band, a research rating against its peers rather than a forecast. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.

What is the ENLV stock price today?

The last price recorded for Enlivex Ltd. (ENLV), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

What are the main risks for ENLV?

The main risks for Enlivex Therapeutics Ltd. include the potential failure to achieve positive results in clinical trials, regulatory delays or rejection of Allocetra, and competition from other companies developing therapies for sepsis and cancer.

What are the key factors to evaluate for ENLV?

Enlivex Ltd. (ENLV) holds a MoonshotScore in the moderate range. To weigh it, start with the trailing P/E under Price & valuation on this page. Allocetra is in Phase II clinical trials for the treatment of organ dysfunction and failure associated with sepsis. Not financial advice.

How frequently does ENLV data refresh on this page?

ENLV's price is the last quote we recorded, from the Nov 19, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.

What has driven ENLV's recent stock price performance?

Enlivex Ltd. (ENLV) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Novel macrophage reprogramming technology. See the News tab for the latest drivers. Past performance does not predict future results.

Should investors consider ENLV overvalued or undervalued right now?

The trailing P/E of Enlivex Ltd. (ENLV) is listed under Price & valuation on this page. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.

Can I buy fractional shares of ENLV?

Fractional-share availability for Enlivex Ltd. (ENLV) depends on your brokerage, account and supported securities. Check the broker's current eligibility, minimums and fees before placing an order.

Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated May 10, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources: the source register lists the 13 figures on this page — 6 from Financial Modeling Prep (FMP), 6 with no recorded source and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.

Publication details and research sources
Published
Research standards
Methodology · Editorial policy · Corrections
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.